People taking the weight loss drug Zepbound experienced dramatically greater weight loss than competitor Wegovy in the first head-to-head trial.
The “difficult decision” was made “in order to protect other vital NHS services”, the National Institute for Health and Care ...
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...
People who took Zepbound, Eli Lilly’s weight loss drug, shed more pounds than those on Novo Nordisk’s Wegovy in a clinical ...
Eli Lilly (NYSE:LLY) said Wednesday its weight-loss drug Zepbound (tirzepatide) provided a 47% greater relative weight loss ...
Mounjaro is a glucagon-like peptide-1 (GLP-1 ... Other GLP-1 agonists include semaglutide – sold under the brand names Wegovy ...
As the Biden administration is proposing drugs like Ozempic and Wegovy be covered by Medicare and Medicaid, Black people need ...
A new study is shedding light on which of two drugs currently approved by the U.S. Food and Drug Administration for weight ...
The guidelines are part of a national trend by municipal governments and private firms struggling to manage ballooning costs ...
Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...
Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy ...